With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
It's summer, so let's talk about this phase 2 trial from UMich published yesterday in JAMA Onc. Patients with locally advanced NSCLC were treated with a PET-adaptive regimen to try and escalate radiation dose as high as possible in 30 fractions while keeping the mean lung dose < 20 Gy. PET was done after 45 Gy, volumes were reduced, and dose per fraction escalated. Median dose was 83 Gy (range: 63-86 Gy). Two-year in-field control was 82% and local/regional control was 62%. RTOG 1106 will compare this regimen to the standard 60 Gy. Looks like dose-escalation for NSCLC may be getting the Grays back together for a reunion tour.